chikungunya virus Archive — Page 1 of 1

March 4, 2021

Chikungunya antibody identified at VUMC moves forward

Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.

By Bill Snyder
September 13, 2019

Early effort to thwart chikungunya infection shows positive results

Phase 1 trial results in new approach to combat the chikungunya

By Bill Snyder
June 14, 2019

New method tested to block chikungunya infection

Scientists are testing a new way to fight chikungunya virus that involves injecting genetic material into the bodies of infected and at-risk individuals to trigger rapid production of potent, virus-neutralizing antibodies.

By Bill Snyder
February 21, 2019

VUMC chikungunya antibody set to enter clinical trial

A monoclonal antibody against the chikungunya virus developed by researchers at Vanderbilt University Medical Center is the first monoclonal antibody encoded by messenger RNA to enter a clinical trial.

By Bill Snyder
May 17, 2018

Alphavirus “Achilles heel”

Targeting the protein that mosquito-borne viruses use to enter cells could be a strategy for preventing infection by multiple emerging viruses.

By Bill Snyder
January 11, 2018

VUMC joins national effort to block global pandemics of potentially lethal viruses

The U.S. Defense Advanced Research Projects Agency (DARPA) has signed a five-year cooperative agreement worth up to $28 million with Vanderbilt University Medical Center (VUMC) to develop methods for preventing the global spread of viruses like chikungunya and Zika.

By Bill Snyder